SCHEMBL3812065

SCHEMBL3812065

Cc1ccc(S(=O)(=O)Oc2nc(N)nc3c2CCCCC32CCCCC2)cc1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2C19 P33261 2/20 0.47
KEAP1 Q14145 1/20 0.40
NFE2L2 Q16236 1/20 0.40
RORC P51449 1/20 0.36
HRH3 Q9Y5N1 3/20 0.35
HRH4 Q9H3N8 2/20 0.35
KMT2A Q03164 3/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
ALDH1A1 P00352 2/20 0.34
P2RY12 Q9H244 1/20 0.34
HSP90AA1 P07900 1/20 0.34
CYP1A2 P05177 1/20 0.34
CYP3A4 P08684 1/20 0.33
CYP2D6 P10635 1/20 0.33
CYP2C9 P11712 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
ENPP3 O14638 1/20 0.32
ENPP1 P22413 1/20 0.32
ENPP2 Q13822 1/20 0.32
TP53 P04637 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341305 0.97 CYP2C19 (0.47) CYP2C19KEAP1NFE2L2RORCHRH3
SCHEMBL3820405 0.90 CYP2C19 (0.42) CYP2C19KEAP1NFE2L2RORCHRH3
SCHEMBL4117844 0.89 CYP2C19 (0.47) CYP2C19KEAP1NFE2L2RORCHRH3
SCHEMBL4129860 0.83 CYP2C19 (0.61) CYP2C19KEAP1NFE2L2HRH3ALDH1A1
SCHEMBL4124782 0.83 CYP2C19 (0.46) CYP2C19KEAP1NFE2L2RORCHRH3
SCHEMBL4139046 0.82 CYP2C19 (0.41) CYP2C19KEAP1NFE2L2RORCKMT2A
SCHEMBL4876866 0.75 ALDH1A1 (0.46) CYP2C19KEAP1NFE2L2HRH3HRH4
SCHEMBL4878194 0.74 ALDH1A1 (0.47) CYP2C19KEAP1NFE2L2HRH3HRH4
SCHEMBL4877590 0.72 CYP2C19 (0.51) CYP2C19KEAP1NFE2L2HRH3KMT2A
SCHEMBL2166315 0.72 ALDH1A1 (0.49) CYP2C19KEAP1NFE2L2HRH3HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8278313-B2 Macrocyclic spiro pyrimidine derivatives ABBOTT LABORATORIES (US) 2012-10-02 US disclosed
US-20090233904-A1 Macrocyclic Spiro Pyrimidine Derivatives ABBOTT LABORATORIES (US) 2009-09-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090233904-A1 Macrocyclic Spiro Pyrimidine Derivatives DPYD, TYMS, TYMP CYP2C19 1385/4885KEAP1 551/4885NFE2L2 1227/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.